Top Tweets for #KEYNOTE671
🔥🚨 @OncoAlert Hot off the press.
Just published @Annals_Oncology
⭐️Five-Year Outcomes of #Keynote671
trial of #Perioperative #Pembrolizumab + chemo vs chemo alone in resectable stage II-IIIB non-small cell #LungCancer (#NSCLC).
✅⬆️5-year #EFS
49.9% (pembro arm) vs 26.5% (HR, 0.58)
✅⬆️5-year #OS
64.6% (pembro arm) vs 53.6% (HR, 0.74)
👇🏻
https://t.co/DPEblT4Rry
At #ELCC2026, long-term data from #KEYNOTE671 continue to redefine expectations in early-stage NSCLC.
https://t.co/esWkRc1UhF
What happens beyond pCR?
🔬 Even patients who did not achieve pCR still derived meaningful benefit from perioperative pembrolizumab:
• Median EFS: 31.9 vs 18.1 months
• 5-year EFS: 43% vs 25%
• HR: 0.69
And for those achieving pCR:
• 5-year EFS: ~81% vs 43%
👉 The message is clear:
Benefit extends beyond pCR, immunotherapy is changing the trajectory of resectable NSCLC.
This is not just about response.
This is about durability.
#LungCancer #NSCLC #Immunotherapy #KEYNOTE671 #ELCC2026 #OncoDaily #OncoDailyLung #MedX #MedTwitter
#KEYNOTE671 is changing how we think about response in early-stage NSCLC.
https://t.co/mpcyaTvFzN
Even when patients do not achieve pCR, perioperative pembrolizumab continues to deliver meaningful benefit.
📊 5-year outcomes:
• Median EFS: 31.9 vs 18.1 months
• Hazard ratio: 0.69
• 5-year EFS: 43% vs 25%
This challenges a long-standing assumption in oncology:
👉 Is pCR the only marker that matters?
At #ELCC2026, updated data show that immunotherapy benefits extend beyond pathological response, reinforcing perioperative pembrolizumab as a standard of care in resectable NSCLC.
The message is clear:
Even without pCR, patients still gain durable benefit.
Martin Reck
#LungCancer #NSCLC #KEYNOTE671 #Immunotherapy #Oncology #CancerResearch #ELCC2026 #OncoDaily #OncoDailyLung #MedX #MedTwitter
6/X #TumorBoardTuesday
📢 OS update in early-stage #NSCLC trials:
✅ #KEYNOTE671 now shows significant OS benefit at IA2
📉 HR 0.72 (95% CI: 0.56–0.93), p=0.0052
📈 3-year OS: 71% (pembro) vs 64% (placebo)
🧾 See OS data across neoadj, periop, and adjuvant trials 👇
#LCSM #OncTwitter
The Cancer News has many updates from #ESMO2023 like this one on KEYNOTE-671 from @LeiDeng3 ⬇️
https://t.co/wPyuQJa1ZJ
#ESMO #cancer #cancernews #Oncology #oncologynews #lungcancer #KEYNOTE671
🔥🚨@OncoAlert Hot off the press
@FDAOncology approves #Perioperative #Pembrolizumab plus Chemo in #patients with resectable stage II, IIIA or IIIB Non-Small Cell #LungCancer (#NSCLC), based on results of #Keynote671 trial that met dual endpoints.
👇🏼
https://t.co/oTfilcYxUC
🔥@OncoAlert Hot off the press
Merck announces #KEYNOTE671 trial, #Neoadjuvant #Pembrolizumab (vs placebo) + chemo followed by #Adjuvant pembro (vs placebo) in pts with resectable stage II,IIIA or IIIB #NSCLC meets primary endpoint of #OverallSurvival.
👇🏼
https://t.co/gJtIzuB4xV
🔥@OncoAlert Hot off the press
Merck announces #KEYNOTE671 trial, #Neoadjuvant #Pembrolizumab (vs placebo) + chemo followed by #Adjuvant pembro (vs placebo) in pts with resectable stage II,IIIA or IIIB #NSCLC meets primary endpoint of #OverallSurvival.
👇🏼
https://t.co/gJtIzuB4xV
🔬Especialistas del Complejo Hospitalario Universitario Insular Materno Infantil han participado en dos estudios que cambiarán el abordaje del #cáncerdepulmón
Más info: ➡️ https://t.co/v5TuXljZHp
#NADIMII @gecp_org
#KEYNOTE671 @MSDEspana
#cáncerdpulmón
#investigacion
‼️Estudios #Keynote671 y #Neotorch: tratamiento perioperatorio en cáncer de pulmón no microcítico
#lcsm #nsclc #pembrolizumab #toripalimab
➡️En @onconius
https://t.co/mO8l5a1bPp
🙋♂️@OncoLucus y @mlazqui
🔥🚨Hot off the press.
#ASCODailyNews #Podcast🎙️featuring two great colleagues & experts, Drs @vamsivelcheti & @JackWestMD, discussing #LungCancer data presented @ASCO #ASCO23 including #ADAURA, #KEYNOTE671 & other major studies.
Podcast & Transcript
👇🏼
https://t.co/XSm0rVnwtA
Publicació a @NEJM de l’estudi #Keynote671 que s’ha presentat a #ASCO23 amb la Dra.Majem entre les coautores!
#orgullsantpau @margamajem https://t.co/xAJPekH8uW
#Keynote671 Presented at #ASCO23 by Dr. Mark Awad #LCSM
EFS, trend toward OS benefit of this neoadj/adj chemo/io strategy vs neoadj chemo alone is impressive- pCR rates of 18% vs 4%
HR 0.42 PDL1>50%, HR 0.51 1-49% and HR0.77 in PDL1 neg (>0.5)
#CM816 + #AEGEAN
Huge congratulations to @hwakeleeMD and colleagues for the great #KEYNOTE671 results at #ASCO23 and @NEJM
🚨🔥@OncoAlert Hot off the press.
Just published @NEJM, in conjunction with presentation @ASCO #ASCO23 by the great Dr. @HwakeleeMD & team:
Results of #Keynote671 Trial:
“Perioperative #Pembrolizumab for Early-Stage Non–Small-Cell #LungCancer”
👇🏼
https://t.co/OYYLrNUPH8
@StephenVLiu @g_mountzios @ASCO @IASLC @myESMO @OncoAlert @DrRoyHerbstYale @JackWestMD @CharuAggarwalMD @DrJNaidoo @HendriksLizza @JordiRemon @peters_solange @MartinReck2 @ElinardouHelena @HwakeleeMD @DrMarkAwad I will set up my ⏰ alarm to make sure I make it to this #KEYNOTE671 presentation @asco #ASCO23 by @HwakeleeMD #lcsm
@DrSteveMartin Dr. Heymach's periop ship cruising the AEGEAN Odyssey like a seasoned captain ⚓️ but wait... are those KEYNOTEs we hear? 🎵⛵️ Could it be the melodious tones of #KEYNOTE671 on the horizon? Ithaca might be closer than we think! 🌅😂 #LungCancer #BattleOfTheTrials"
Our 2nd @CancerTrialCork patient commenced #Keynote671 #clinicaltrial this morning: preop chemo +/- #pembro in resectable lung cancer
Open at @CUH_Cork, @stjamesdublin & UHL (check https://t.co/yK4jZ1BQAe)
Great to have 🇮🇪 access to international trials like this @MSDInvents
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers